share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024财年二季报
美股SEC公告 ·  2024/08/13 05:31

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. reported a net loss of $5.4 million for Q2 2024, compared to $2.1 million in Q2 2023, with total operating expenses increasing to $3.1 million from $1.3 million year-over-year. The company ended the quarter with $0.2 million in cash and cash equivalents, down from $4.2 million at the end of 2023, reflecting ongoing investments in research and development activities.The company recently strengthened its pipeline through a significant licensing agreement with AstraZeneca on August 7, 2024, gaining exclusive rights to HK-4 Glucokinase activators and a myeloperoxidase inhibitor. To support operations, Conduit secured a $2.65 million senior secured promissory note from Nirland Limited and issued 12.5 million shares of common stock.Management has identified the need for additional financing to fund operations for the next 12 months, with working capital requirements estimated at $17.1 million. The company received a Nasdaq deficiency notice on August 12, 2024, regarding its stock price falling below $1.00 per share minimum requirement, with until February 10, 2025, to regain compliance.
Conduit Pharmaceuticals Inc. reported a net loss of $5.4 million for Q2 2024, compared to $2.1 million in Q2 2023, with total operating expenses increasing to $3.1 million from $1.3 million year-over-year. The company ended the quarter with $0.2 million in cash and cash equivalents, down from $4.2 million at the end of 2023, reflecting ongoing investments in research and development activities.The company recently strengthened its pipeline through a significant licensing agreement with AstraZeneca on August 7, 2024, gaining exclusive rights to HK-4 Glucokinase activators and a myeloperoxidase inhibitor. To support operations, Conduit secured a $2.65 million senior secured promissory note from Nirland Limited and issued 12.5 million shares of common stock.Management has identified the need for additional financing to fund operations for the next 12 months, with working capital requirements estimated at $17.1 million. The company received a Nasdaq deficiency notice on August 12, 2024, regarding its stock price falling below $1.00 per share minimum requirement, with until February 10, 2025, to regain compliance.
Conduit Pharmaceutical Inc. 报告称2024年第二季度净亏损为540万美金,较2023年第二季度的210万美金有所增加,营业费用同比增加至310万美金,从130万美金上升。公司在本季度末现金及现金等价物为20万美金,较2023年底的420万美金下降,这反映了公司在研究和开发活动中的持续投资。公司最近通过与阿斯利康在2024年8月7日签署的重要许可协议,增强了其产品管道,获得了Hk-4 葡萄糖激酶激活剂和髓过氧化物酶抑制剂的独占权利。为了支持运营,Conduit从Nirland Limited获得了265万美金的高级担保本票,并发行了1250万股普通股。管理层已识别出在未来12个月内为运营提供额外融资的需求,流动资金需求估计为1710万美金。公司在2024年8月12日收到了纳斯达克的缺陷通知,因其股票价格低于每股1.00美金的最低要求,并有直到2025年2月10日的时间来恢复合规。
Conduit Pharmaceutical Inc. 报告称2024年第二季度净亏损为540万美金,较2023年第二季度的210万美金有所增加,营业费用同比增加至310万美金,从130万美金上升。公司在本季度末现金及现金等价物为20万美金,较2023年底的420万美金下降,这反映了公司在研究和开发活动中的持续投资。公司最近通过与阿斯利康在2024年8月7日签署的重要许可协议,增强了其产品管道,获得了Hk-4 葡萄糖激酶激活剂和髓过氧化物酶抑制剂的独占权利。为了支持运营,Conduit从Nirland Limited获得了265万美金的高级担保本票,并发行了1250万股普通股。管理层已识别出在未来12个月内为运营提供额外融资的需求,流动资金需求估计为1710万美金。公司在2024年8月12日收到了纳斯达克的缺陷通知,因其股票价格低于每股1.00美金的最低要求,并有直到2025年2月10日的时间来恢复合规。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息